Olgu Sunumu
BibTex RIS Kaynak Göster

Yıl 2019, Cilt: 9 Sayı: 1, 91 - 93, 29.03.2019

Selami Aykut Temiz Arzu Ataseven İlkay Ozer Recep Dursun Siddika Findik

https://doi.org/10.33808/marusbed.546841
Cited By: 1

Öz

Kaynakça

  • [1] Davis MDP, van der Hilst JCH. Mimickers of Urticaria: Urticarial Vasculitis and Autoinflammatory Diseases. J Allergy Clin Immunol Pract 2018;6(4):1162-70.
  • [2] Sjöwall C, Mandl T, Skattum L, Olsson M, Mohammad AJ. Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). Rheumatology (Oxford) 2018; 57(8):1400- 07.
  • [3] Kavala M, Türkoğlu Z, Özlü E. Metotreksat ve dermatolojide klinik kullanımları. Med Med J 2014; 29:104-110.
  • [4] Sunderkötter C, De Groot K. Therapie von Vaskulitiden und Vaskulopathien. Der Hautarzt 2008; 59:382.
  • [5] Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003; 48:311-40.
  • [6] Polat AK, Belli AA, Karakus V, Dere Y. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome. An Bras Dermatol 2017; 92:59-61.
  • [7] Black AK. Urticarial vasculitis. Clinics in Dermatology 1999; 17:565-69.
  • [8] Katsambas A, Riga P. Purpura and vasculitis: unapproved treatments. Clin Dermatol 2002; 20:626-33.
  • [9] Khasnis A, Langford CA. Update on vasculitis. J Allergy Clin Immunol 2009; 123:1226-36.
  • [10] 1Shen S, O’Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53:1-18.
  • [11] Thomas-Golbanov C, Sridharan S. Novel therapies in vasculitis. Expert Opin Investig Drugs 2001; 10:1279-89.
  • [12] Stack PS. Methotrexate for urticarial vasculitis. Ann Allergy 1994; 72:36-38.
  • [13] Perez A, Woods A, Grattan CEH. Methotrexate: a useful steroidsparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162:191-94.
  • [14] Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43:14-21.
  • [15] Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Review of Clinical Immunology 2014; 10:1519-30.

Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?

Yıl 2019, Cilt: 9 Sayı: 1, 91 - 93, 29.03.2019

Selami Aykut Temiz Arzu Ataseven İlkay Ozer Recep Dursun Siddika Findik

https://doi.org/10.33808/marusbed.546841
Cited By: 1

Öz

Objective: Urticarial vasculitis is a chronic clinicopathologic entity characterized by clinically characterized urticarial rash, histopathologically
characterized by leukocytoclastic vasculitis. The pathogenesis is thought to be developed by a type III hypersensitivity reaction similar to
leukocytoclastic vasculitis.
Methods: Antihistamines and/or corticosteroids (systemic/local) may be used in patients with limited normocomplementemic urticarial vasculitis.
In the literature, severe cases treated with dapsone, colchicine, hydroxychloroquine, pentoxifylline, omalizumab, mycophenolate mofetil, rituximab,
cyclosporine, intravenous immunoglobulin, and cyclophosphamide have been reported in the case reports.
Results: In this case, the patient, whose symptoms had not previously responded to treatment with antihistamines, steroids, cyclosporine, and
omalizumab, responded to treatment with methotrexate.
Conclusion: This case report recommends that methotrexate therapy may be a treatment option for cases of resistant urticarial vasculitis.

Anahtar Kelimeler

Urticarial vasculitis methotrexate omalizumab

Kaynakça

  • [1] Davis MDP, van der Hilst JCH. Mimickers of Urticaria: Urticarial Vasculitis and Autoinflammatory Diseases. J Allergy Clin Immunol Pract 2018;6(4):1162-70.
  • [2] Sjöwall C, Mandl T, Skattum L, Olsson M, Mohammad AJ. Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). Rheumatology (Oxford) 2018; 57(8):1400- 07.
  • [3] Kavala M, Türkoğlu Z, Özlü E. Metotreksat ve dermatolojide klinik kullanımları. Med Med J 2014; 29:104-110.
  • [4] Sunderkötter C, De Groot K. Therapie von Vaskulitiden und Vaskulopathien. Der Hautarzt 2008; 59:382.
  • [5] Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003; 48:311-40.
  • [6] Polat AK, Belli AA, Karakus V, Dere Y. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome. An Bras Dermatol 2017; 92:59-61.
  • [7] Black AK. Urticarial vasculitis. Clinics in Dermatology 1999; 17:565-69.
  • [8] Katsambas A, Riga P. Purpura and vasculitis: unapproved treatments. Clin Dermatol 2002; 20:626-33.
  • [9] Khasnis A, Langford CA. Update on vasculitis. J Allergy Clin Immunol 2009; 123:1226-36.
  • [10] 1Shen S, O’Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53:1-18.
  • [11] Thomas-Golbanov C, Sridharan S. Novel therapies in vasculitis. Expert Opin Investig Drugs 2001; 10:1279-89.
  • [12] Stack PS. Methotrexate for urticarial vasculitis. Ann Allergy 1994; 72:36-38.
  • [13] Perez A, Woods A, Grattan CEH. Methotrexate: a useful steroidsparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162:191-94.
  • [14] Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43:14-21.
  • [15] Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Review of Clinical Immunology 2014; 10:1519-30.
Toplam 15 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Case Report
Yazarlar

Selami Aykut Temiz 0000-0003-4878-0045

Arzu Ataseven Bu kişi benim 0000-0001-5372-0712

İlkay Ozer Bu kişi benim 0000-0001-6170-0930

Recep Dursun Bu kişi benim 0000-0002-1279-574X

Siddika Findik Bu kişi benim 0000-0002-3364-7498

Yayımlanma Tarihi 29 Mart 2019
Gönderilme Tarihi 16 Nisan 2018
Yayımlandığı Sayı Yıl 2019 Cilt: 9 Sayı: 1

Kaynak Göster

APA Temiz, S. A., Ataseven, A., Ozer, İ., Dursun, R., vd. (2019). Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences, 9(1), 91-93. https://doi.org/10.33808/marusbed.546841
AMA Temiz SA, Ataseven A, Ozer İ, Dursun R, Findik S. Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences. Mart 2019;9(1):91-93. doi:10.33808/marusbed.546841
Chicago Temiz, Selami Aykut, Arzu Ataseven, İlkay Ozer, Recep Dursun, ve Siddika Findik. “Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?”. Clinical and Experimental Health Sciences 9, sy. 1 (Mart 2019): 91-93. https://doi.org/10.33808/marusbed.546841.
EndNote Temiz SA, Ataseven A, Ozer İ, Dursun R, Findik S (01 Mart 2019) Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences 9 1 91–93.
IEEE S. A. Temiz, A. Ataseven, İ. Ozer, R. Dursun, ve S. Findik, “Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?”, Clinical and Experimental Health Sciences, c. 9, sy. 1, ss. 91–93, 2019, doi: 10.33808/marusbed.546841.
ISNAD Temiz, Selami Aykut vd. “Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?”. Clinical and Experimental Health Sciences 9/1 (Mart 2019), 91-93. https://doi.org/10.33808/marusbed.546841.
JAMA Temiz SA, Ataseven A, Ozer İ, Dursun R, Findik S. Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences. 2019;9:91–93.
MLA Temiz, Selami Aykut vd. “Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?”. Clinical and Experimental Health Sciences, c. 9, sy. 1, 2019, ss. 91-93, doi:10.33808/marusbed.546841.
Vancouver Temiz SA, Ataseven A, Ozer İ, Dursun R, Findik S. Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences. 2019;9(1):91-3.

Cited By

Case of benralizumab‐induced exacerbations of chronic spontaneous urticaria
Clinical Case Reports
https://doi.org/10.1002/ccr3.5930
 Kapak Resmi İndir

14639   14640